positions available now

PBAC Special Meeting – August 2018

The August 2018 PBAC special meeting is scheduled for 17 August 2018 to consider options for listing PD-1 and PD-L1 checkpoint inhibitors for the treatment of multiple tumours (pan-tumour indications) on the PBS. Here, the Commercial Eyes Market Access team provides an overview of previous PD-1 and PD-L1 inhibitors submissions, including an additional analysis conducted on post listing utilisation.


The Commercial Eyes Market Access can help you navigate Australia and New Zealand’s sophisticated and mature systems of Health Technology Assessment. Contact us on (03) 9251 0777 to learn more about our PBAC Outcomes Database and let us help you envisage, achieve and defend the optimum market access outcomes for your business.

This entry was posted in Market Access, PBAC and tagged , , , , , .
Copyright © 2020 Commercial Eyes